Progenics Pharmaceuticals Inc. (PGNX) Upgraded to "Hold" at Zacks Investment Research

Progenics Pharmaceuticals Inc. (PGNX) Upgraded to "Hold" at Zacks Investment Research


According to Zacks, "Progenics Pharmaceuticals, Inc. is developing innovative medicines for oncology, with a pipeline that includes several product candidates in later-stage clinical development. Progenics' first-in-class PSMA-targeted technology platform for prostate cancer includes an antibody drug conjugate therapeutic in a two-cohort phase 2 clinical trial and a small molecule imaging agent that has completed patient dosing in a phase 2 trial.



from Biotech News